The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata

Brain Research

Volumn 735, Issue 2, 1996, Pages 208-216

  Löscher, Wolfgang ^a   Hönack, Dagmar ^a   Bloms Funke, Petra ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Anticonvulsant; Epilepsy; Glutamate decarboxylase; Aminobutyric acid

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; AMINOOXYACETIC ACID; ANTICONVULSIVE AGENT; ETIRACETAM;

ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EPILEPSY; FEMALE; GABAERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0030574062     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00587-2     Document Type: Article

References (26)

1. [1] Adams, J.C., Heavy metal intensification of DAB-based HRP reaction product, J. Histochem. Cytochem., 29 (1981) 775.
2. [2] Bunney, B.S., Walters J.R., Roth, R.H. and Aghajanian, G.K., Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity, J. Pharmacol. Exp. Ther., 185 (1973) 560-571.
3. [3] Gale, K., Progression and generalization of seizure discharge: anatomical and neurochemical substrates, Epilepsia, 29 (Suppl. 2) (1988) S15-S34.
4. [4] Gale, K., GABA and epilepsy: basic concepts from preclinical research, Epilepsia, 33 (Suppl. 5) (1992) S3-S12.
5. [5] Gale, K. and Casu, M., Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications. Mol. Cell. Biochem., 39 (1981) 369-405.
6. [6] Gillard, M., Noyer, M., Hénichart, J.P. and Wülfert, E., The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes, Br. J. Pharmacol., 112 (1994) 615P.
7. [7] Gower, A.J., Hirsch, E., Boehrer, A., Noyer, M. and Marescaux, C., Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy, Epilepsy Res., 22 (1995) 207-213.
8. [8] Gower, A.J., Noyer, M., Verloes, R., Gobert, J. and Wülfert, E., ucb L059, a novel anti-convulsant drug: pharmacological profile in animals, Eur. J. Pharmacol., 222 (1992) 193-203.
9. [9] Guyenet, P.G. and Aghajanian, G.K., Antidromic identification of dopaminergic and other output neurons of the rat substantia nigra, Brain Res., 150 (1978) 69-84.
10. [10] Löscher, W., Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA, J. Neurochem., 34 (1980) 1603-1608.
11. [11] Löscher, W., GABA and the epilepsies. Experimental and clinical considerations. In N.G. Bowery and G. Nisticò (Eds.), GABA. Basic Research and Clinical Applications, Pythagora Press, Rome, 1989, pp. 260-300.
12. [12] Löscher, W. and Ebert, U., Basic mechanisms of seizure propagation: Targets for rational drug design and rational polypharmacy, Epilepsy Res. Suppl., (1996) in press.
13. [13] Löscher, W. and Hönack, D., Profile of ucb L059, a novel anticon vulsant drug, in models of partial and generalized epilepsy in mice and rats, Eur. J. Pharmacol., 232 (1993) 147-158.
14. [14] Löscher, W., Hönack, D. and Gramer, M., Use of inhibitors of γ-aminobutyric acid (GABA) transaminase for the estimation of GABA turnover in various brain regions of rats: a reevaluation of aminooxyacetic acid, J. Neurochem., 53 (1989) 1737-1750.
15. [15] Löscher, W., Rohlfs, A. and Rundfeldt, C., Reduction in firing rate of substantia nigra pars reticulata neurons by valproate: influence of different types of anesthesia in rats. Brain Res., 702 (1995) 133-144.
16. [16] Löscher, W. and Schmidt, D., New drugs for the treatment of epilepsy, Curr. Opin. Invest. Drugs, 2 (1993) 1067-1095.
17. [17] McGeer, E.G., Staines, W.A. and McGeer, P.L., Neurotransmitters in the basal ganglia, Can. J. Neural Sci., 11 (1984) 89-99.
18. [18] Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P. and Wülfert, E., The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes, Eur. J. Pharmacol., 286 (1995) 137-146.
19. [19] Paxinos, G. and Watson, C., The Rat Brain in Stereotomic Coordinates, Academic Press, Sydney, 1986.
20. [20] Rosenberg, D.R., Wright, B.A. and Gershon, S., Cognitive enhancing agents for the treatment of senile dementia of the Alzheimer's type, Drugs Today, 7 (1990) 449-471.
21. [21] Simons, D.J. and Land, P.W.A., A reliable technique for marking the location of extracellular recording sites using glass micropipettes, Neurosci. Lett., 81 (1987) 100-104.
22. [22] Stables, J.P., Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P. and Perucca, E., Progress report on new antiepileptic drugs, A summary of the second Eilat conference, Epilepsy Res., 22 (1995) 235-246.
23. [23] Turski, L., Cavalheiro, E.A., Calderazzo-Filho, L.S., Bortolotto, Z.A., Klock-gether, T., Ikonomidou, C. and Turski, W.A., The basal ganglia, the deep prepyriform cortex, and seizure spread: bicuculline is anticonvulsant in the rat striatum, Proc. Natl. Acad. Sci. USA, 86 (1989) 1694-1697.
24. [24] Verloes, R., Scotto, A.M., Gobert, J. and Wülfert, E., Effects of nootropic drugs in a scopolamine-induced amnesia model in mice, Psychopharmacology, 95 (1988) 226-230.
25. [25] Walker, M.C., Sharief, M.K., Sander, J.W.A.S., Patsalos, P.N. and Shorvon, S.D., Early experience with ucb L059 in refractory epilepsy, Epilepsia, 35 (Suppl. 7) (1994) 76.
26. [26] Waszczak, B.L., Lee, E.K. and Walters, J.R., Effects of anticonvulsant drugs on substantia nigra pars reticulata neurons, J. Pharmacol. Exp. Ther., 239 (1986) 606-611.